<DOC>
	<DOCNO>NCT00504127</DOCNO>
	<brief_summary>To study efficacy safety Naproxcinod vs. Naproxen Placebo indication sign symptom osteoarthritis</brief_summary>
	<brief_title>Efficacy Safety Study Naproxcinod Subjects With Osteoarthritis Knee</brief_title>
	<detailed_description>This 53 week study consist 26 week randomize , double-blind , parallel group , multicenter study compare efficacy safety Naproxcinod , Placebo Naproxen . The first 26 week follow naproxen-controlled treatment period 52 week 1-week post-treatment safety follow-up .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<mesh_term>Naproxen-n-butyl nitrate</mesh_term>
	<criteria>Men Woman ( 40 old ) diagnosis primary OA knee . Must current chronic user NSAIDS acetaminophen Must discontinue analgesic therapy Screening Uncontrolled Hypertension Diabetes Hepatic Renal Impairment Current expect use anticoagulant Clinical relevant abnormal ECG A history alcohol drug abuse Candidates imminent joint replacement Participation within 30 day prior screen another investigational study</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Arthritis</keyword>
	<keyword>Degenerative</keyword>
</DOC>